within Pharmacolibrary.Drugs.V_Various.V03A_AllOtherTherapeuticProducts.V03AF12_Trilaciclib;

model Trilaciclib
  extends Pharmacolibrary.Drugs.ATC.V.V03AF12;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>V03AF12</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Trilaciclib is an intravenously administered, selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor used to reduce the frequency and severity of chemotherapy-induced myelosuppression in adults receiving certain chemotherapeutic regimens for extensive-stage small cell lung cancer (ES-SCLC). Trilaciclib is FDA-approved for this indication. It is not used as an anticancer agent directly, but as a myeloprotective agent to help patients tolerate myelosuppressive chemotherapy.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic model for adult cancer patients (predominantly ES-SCLC) receiving intravenous trilaciclib; parameters from first-in-human, phase 2, and phase 3 studies.</p><h4>References</h4><ol><li><p>Cheng, Y, et al., &amp; Zhou, L (2024). Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES). <i>Lung cancer (Amsterdam, Netherlands)</i> 188 107455–None. DOI:<a href=\"https://doi.org/10.1016/j.lungcan.2023.107455\">10.1016/j.lungcan.2023.107455</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38224653/\">https://pubmed.ncbi.nlm.nih.gov/38224653</a></p></li><li><p>Weiss, JM, et al., &amp; Dragnev, KH (2019). Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. <i>Annals of oncology : official journal of the European Society for Medical Oncology</i> 30(10) 1613–1621. DOI:<a href=\"https://doi.org/10.1093/annonc/mdz278\">10.1093/annonc/mdz278</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31504118/\">https://pubmed.ncbi.nlm.nih.gov/31504118</a></p></li><li><p>Li, C, et al., &amp; Beelen, A (2023). Population pharmacokinetics and exposure-response of trilaciclib in extensive-stage small cell lung cancer and triple-negative breast cancer. <i>British journal of clinical pharmacology</i> 89(3) 1067–1079. DOI:<a href=\"https://doi.org/10.1111/bcp.15549\">10.1111/bcp.15549</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36180417/\">https://pubmed.ncbi.nlm.nih.gov/36180417</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Trilaciclib;
